Latest On Voyager Therapeutics, Inc (VYGR):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-09 19:46 EST | News | Voyager Therapeutics GAAP EPS of $2.94 beats by $1.90, revenue of $150.48M beats by $97.98M | N/A |  |
| 2023-05-09 19:45 EST | News | Voyager Therapeutics, Inc. (VYGR) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-05-08 16:52 EST | News | Voyager Therapeutics Q1 2023 Earnings Preview | N/A | |
| 2023-04-02 18:12 EST | News | Voyager: Preclinical Company With Major Big Pharma Deals | N/A | |
| 2023-03-08 02:10 EST | News | Voyager Therapeutics, Inc. (VYGR) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-03-07 11:26 EST | News | Voyager Therapeutics GAAP EPS of -$0.61 misses by $0.06 | N/A | |
| 2023-03-06 20:49 EST | News | Voyager stock pops on getting $25M from Novartis under license deal | N/A | |
| 2023-03-06 20:49 EST | News | Voyager Therapeutics Q4 2022 Earnings Preview | N/A | |
| 2023-01-14 15:17 EST | News | Voyager: Recent Neurocrine Deal Signals More Upside | N/A | |
| 2023-01-09 21:48 EST | News | Voyager jumps 29% on licensing deal with Neurocrine | N/A | |
| 2022-11-08 21:06 EST | News | Voyager Therapeutics GAAP EPS of $0.45 beats by $0.79, revenue of $41.1M beats by $32.07M | N/A | |
| 2022-11-08 21:05 EST | News | Voyager Therapeutics, Inc. (VYGR) Q3 2022 Earnings Call Transcript | N/A | |
| 2022-11-08 02:33 EST | News | Voyager Therapeutics Q3 2022 Earnings Preview | N/A | |
| 2022-10-04 22:59 EST | News | Voyager stock rises as Pfizer opts to use AAV capsid for neurologic disease target | N/A | |
| 2022-09-07 09:01 EST | News | Voyager Therapeutics hires new finance chief | N/A | |
| 2022-08-07 13:19 EST | News | Voyager Therapeutics, Inc. (VYGR) CEO Dr. Al Sandrock on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-08-04 18:40 EST | News | Voyager Therapeutics GAAP EPS of -$0.50 misses by $0.02 | N/A | |
| 2022-06-09 02:25 EST | News | Looking Back In On Voyager Therapeutics | N/A | |
| 2022-05-05 12:49 EST | News | Voyager Therapeutics GAAP EPS of -$0.56, revenue of $0.7M misses by $12.01M | N/A | |
| 2022-04-22 03:14 EST | News | Voyager Therapeutics plunges as board members depart | N/A | |
| 2022-03-26 15:30 EST | News | Voyager Does A Reboot After First Generation Failures | N/A | |
| 2022-03-23 17:18 EST | News | Dr. Alfred W. Sandrock is the new CEO at Voyager therapeutics | N/A | |
| 2022-03-08 21:42 EST | News | Voyager stock soars 15% on license deal with Novartis for AAV capsids for gene therapies | N/A | |
| 2022-03-08 21:42 EST | News | Voyager Therapeutics GAAP EPS of $0.15 beats by $0.47, revenue of $28.07M beats by $13.52M | N/A | |
| 2021-11-21 14:11 EST | News | Voyager Therapeutics: Another Year, Another Deal | N/A | |
| 2021-11-03 01:45 EST | News | Voyager Therapeutics EPS beats by $0.10, misses on revenue | N/A | |
| 2021-10-20 17:49 EST | News | Voyager Therapeutics falls despite gene therapy shows activity in preclinical study | N/A | |
| 2021-10-07 20:51 EST | News | Baird upgrades Voyager Therapeutics to outperform on Pfizer deal; sees ~133% upside | N/A | |
| 2021-10-06 20:28 EST | News | Pfizer in pact with Voyager Therapeutics to develop gene therapies | N/A | |
| 2021-09-22 10:09 EST | News | Voyager Therapeutics (VYGR) Investor Presentation - Slideshow | N/A | |
| 2021-08-13 23:16 EST | News | Voyager Therapeutics (VYGR) Presents At Canaccord Genuity Growth Conference Fireside Chat | N/A | |
| 2021-08-09 17:17 EST | News | Voyager launches new programs in Huntington's disease, ALS, and spinal muscular atropny | N/A | |
| 2021-07-22 08:38 EST | News | Vectoring In On Voyager Therapeutics | N/A | |
| 2021-04-26 09:15 EST | News | Voyager shares rise as FDA lifts clinical hold on Huntington’s disease treatment IND | N/A | |
| 2021-03-02 01:07 EST | Analyst Rating | The Analyst Target Price has decreased from $10.35 to $10.25. | Neutral | |
| 2021-03-01 12:35 EST | Analyst Rating | The Analyst Target Price has decreased from $11.55 to $10.35. | Neutral | |
| 2021-02-28 12:49 EST | Financials | Company financials have been released. | Neutral | |
| 2021-02-28 00:50 EST | Financials | Company financials have been released. | Neutral | |
| 2021-02-27 03:47 EST | News | Premarket analyst action - healthcare | N/A | |
| 2021-02-27 00:58 EST | Financials | Company financials have been released. | Neutral | |
| 2021-02-26 09:20 EST | News | Voyager Therapeutics EPS beats by $0.13, misses on revenue | N/A | |
| 2021-02-26 09:19 EST | News | Voyager Therapeutics, Inc. (VYGR) CEO Andre Turenne on Q4 2020 Results - Earnings Call Transcript | N/A | |
| 2021-02-26 04:54 EST | Earnings Estimate | An EPS average of -$2.86 is estimated for the 2022 year. | Sell | |
| 2021-02-26 04:54 EST | Earnings Estimate | An EPS average of -$0.55 is estimated for the quarter ending on June 30, 2021. | Sell | |
| 2021-02-04 12:59 EST | Analyst Rating | The Analyst Target Price has decreased from $14.09 to $11.55. | Neutral | |
| 2021-02-04 03:50 EST | News | Voyager sinks after BITG cut citing multiple clinical holds | N/A | |
| 2021-02-03 09:03 EST | News | Voyager gets termination notice for Neurocrine Parkinson’s collaboration | N/A | |
| 2021-01-19 04:47 EST | News | Voyager Therapeutics: Complicated Story In Gene Therapy Development | N/A | |
| 2020-12-24 17:20 EST | Analyst Rating | The Analyst Target Price has decreased from $14.75 to $14.09. | Neutral | |
| 2020-12-23 17:23 EST | Analyst Rating | The Analyst Target Price has decreased from $15.33 to $14.75. | Neutral | |
About Voyager Therapeutics, Inc (VYGR):
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia. The company has strategic collaboration agreements with the University of Massachusetts; and ClearPoint Neuro, Inc., as well as collaborations with Thermo Fisher Scientific and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs. It also has a collaboration and license agreement with Neurocrine Biosciences, Inc. for the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
General
- Name Voyager Therapeutics, Inc
- Symbol VYGR
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 177
- Fiscal Year EndDecember
- IPO Date2015-11-11
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.voyagertherapeutics.com
View More
Valuation
- Trailing PE 5.57
- Price/Sales (Trailing 12 Mt.) 1.26
- Price/Book (Most Recent Quarter) 1.41
- Enterprise Value Revenue 0.49
- Enterprise Value EBITDA 2.7
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$2.84
- Next Year EPS Estimate -$2.97
- Next Quarter EPS Estimate -$0.51
- Profit Margin 21%
- Operating Margin 16%
- Return on Assets 6%
- Return on Equity 29%
- Revenue 171.13 million
- Earnings Per Share $0.98
- Revenue Per Share $4.61
- Gross Profit 62.38 million
- Quarterly Earnings Growth -80%
View More
Highlights
- Market Capitalization 205.59 million
- EBITDA 31.2 million
- PE Ratio 3.11
- Analyst Target Price $10.25
- Book Value Per Share $4.13
View More
Share Statistics
- Shares Outstanding 37.65 million
- Shares Float 22.58 million
- % Held by Insiders 1407%
- % Held by Institutions 74.93%
- Shares Short 1.99 million
- Shares Short Prior Month 1.89 million
- Short Ratio 3.56
- Short % of Float 8%
- Short % of Shares Outstanding 5%
View More
Technicals
- Beta 1.06
- 52 Week High $14.62
- 52 Week Low $5.18
- 50 Day Moving Average 6.61
- 200 Day Moving Average 8.94
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Voyager Therapeutics, Inc (VYGR) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Voyager Therapeutics, Inc (VYGR) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-02-25 | $N/A | -$0.43 | -$0.56 | 23.46% |
| 2020-09-30 | 2020-11-09 | $N/A | $2.27 | -$0.10 | 2416.33% |
| 2020-06-30 | 2020-08-10 | $N/A | -$0.23 | -$0.73 | 68.61% |
| 2020-03-31 | 2020-05-06 | $18.07 million | -$0.66 | -$0.79 | 16.61% |
| 2019-12-31 | 2020-03-03 | $32.67 million | -$0.34 | -$0.81 | 57.93% |
| 2019-09-30 | 2019-11-06 | $20.43 million | -$0.41 | -$0.73 | 43.84% |
| 2019-06-30 | 2019-08-09 | $46.09 million | $0.29 | -$0.81 | 135.71% |
| 2019-03-31 | 2019-05-07 | $5.2 million | -$0.81 | -$0.78 | -4.03% |
| 2018-12-31 | 2019-02-26 | $2.01 million | -$0.70 | -$0.71 | 1.71% |
| 2018-09-30 | 2018-11-07 | $2.09 million | -$0.63 | -$0.79 | 20.36% |
| 2018-06-30 | 2018-08-07 | $2.58 million | -$0.80 | -$0.66 | -20.61% |
| 2018-03-31 | 2018-05-10 | $942000 | -$0.63 | -$0.62 | -1.61% |
| 2017-12-31 | 2018-03-14 | $6.35 million | -$0.40 | -$0.73 | 44.87% |
| 2017-09-30 | 2017-11-02 | $1.15 million | -$0.89 | -$0.72 | -23.15% |
| 2017-06-30 | 2017-08-08 | $1.18 million | -$0.73 | -$0.61 | -20.66% |
| 2017-03-31 | 2017-05-09 | $1.46 million | -$0.65 | -$0.53 | -23.32% |
| 2016-12-31 | 2017-03-15 | $2.36 million | -$0.57 | -$0.46 | -24.37% |
| 2016-09-30 | 2016-11-10 | $3.31 million | -$0.35 | -$0.41 | 14.22% |
| 2016-06-30 | 2016-08-11 | $3.72 million | -$0.37 | -$0.34 | -8.82% |
| 2016-03-31 | 2016-05-12 | $4.83 million | -$0.29 | -$0.35 | 17.92% |
| 2015-12-31 | 2016-03-17 | $4.94 million | -$0.67 | -$0.62 | -8.06% |
| 2015-09-30 | 2015-11-16 | $4.94 million | -$5.25 | -$3.48 | -50.86% |
Voyager Therapeutics, Inc (VYGR) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Voyager Therapeutics, Inc (VYGR) Chart:
Voyager Therapeutics, Inc (VYGR) News:
Below you will find a list of latest news for Voyager Therapeutics, Inc (VYGR) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Voyager Therapeutics, Inc (VYGR) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2024-05-17 | 2.5 | 0 | CALL | 0 | 0 | 287.17 | TRUE | 0 | 0 |
| 2024-05-17 | 5 | 4.75 | CALL | 0 | 40 | 249.39 | TRUE | 0 | 0 |
| 2024-05-17 | 7.5 | 0.55 | CALL | 5 | 93 | 119.48 | TRUE | -0.25 | -0.31 |
| 2024-05-17 | 10 | 0.1 | CALL | 18 | 248 | 90.6 | FALSE | 0.1 | 0 |
| 2024-05-17 | 12.5 | 0.05 | CALL | 0 | 50 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 15 | 0.27 | CALL | 0 | 26 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 17.5 | 0.2 | CALL | 0 | 1 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 20 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 2.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 5 | 0.05 | PUT | 0 | 20 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 7.5 | 0.65 | PUT | 8 | 208 | 94.46 | FALSE | 0.05 | 0.08 |
| 2024-05-17 | 10 | 2.34 | PUT | 0 | 86 | 88.58 | TRUE | 0 | 0 |
| 2024-05-17 | 12.5 | 2.55 | PUT | 0 | 10 | 297.06 | TRUE | 0 | 0 |
| 2024-05-17 | 15 | 0 | PUT | 0 | 0 | 350.38 | TRUE | 0 | 0 |
| 2024-05-17 | 17.5 | 0 | PUT | 0 | 0 | 386.78 | TRUE | 0 | 0 |
| 2024-05-17 | 20 | 0 | PUT | 0 | 0 | 409.28 | TRUE | 0 | 0 |
| 2024-06-21 | 2.5 | 0 | CALL | 0 | 0 | 360.38 | TRUE | 0 | 0 |
| 2024-06-21 | 5 | 0 | CALL | 0 | 0 | 134.73 | TRUE | 0 | 0 |
| 2024-06-21 | 7.5 | 0.95 | CALL | 0 | 2 | 74.79 | TRUE | 0 | 0 |
| 2024-06-21 | 10 | 0.25 | CALL | 1 | 16 | 74.85 | FALSE | -0.09 | -0.26 |
| 2024-06-21 | 12.5 | 0 | CALL | 0 | 0 | 89.33 | FALSE | 0 | 0 |
| 2024-06-21 | 15 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 2.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 7.5 | 0.8 | PUT | 0 | 18 | 62.33 | FALSE | 0 | 0 |
| 2024-06-21 | 10 | 0 | PUT | 0 | 0 | 164.98 | TRUE | 0 | 0 |
| 2024-06-21 | 12.5 | 0 | PUT | 0 | 0 | 183.86 | TRUE | 0 | 0 |
| 2024-06-21 | 15 | 0 | PUT | 0 | 0 | 184.88 | TRUE | 0 | 0 |
| 2024-07-19 | 2.5 | 0 | CALL | 0 | 0 | 357.47 | TRUE | 0 | 0 |
| 2024-07-19 | 5 | 2.9 | CALL | 15 | 78 | 95.77 | TRUE | 2.9 | 0 |
| 2024-07-19 | 7.5 | 1.1 | CALL | 217 | 503 | 70.78 | TRUE | 1.1 | 0 |
| 2024-07-19 | 10 | 0.4 | CALL | 10 | 182 | 73.55 | FALSE | -0.05 | -0.11 |
| 2024-07-19 | 12.5 | 0.4 | CALL | 0 | 71 | 79.35 | FALSE | 0 | 0 |
| 2024-07-19 | 15 | 0.05 | CALL | 0 | 129 | 230.91 | FALSE | 0 | 0 |
| 2024-07-19 | 17.5 | 0.5 | CALL | 0 | 7 | 0 | FALSE | 0 | 0 |
| 2024-07-19 | 20 | 0.2 | CALL | 0 | 31 | 0 | FALSE | 0 | 0 |
| 2024-07-19 | 2.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-07-19 | 5 | 0.27 | PUT | 0 | 173 | 82.56 | FALSE | 0 | 0 |
| 2024-07-19 | 7.5 | 0.95 | PUT | 0 | 246 | 73.08 | FALSE | 0 | 0 |
| 2024-07-19 | 10 | 2.5 | PUT | 0 | 94 | 68.64 | TRUE | 0 | 0 |
| 2024-07-19 | 12.5 | 4.2 | PUT | 0 | 7 | 95.78 | TRUE | 0 | 0 |
| 2024-07-19 | 15 | 6.1 | PUT | 0 | 0 | 132.8 | TRUE | 0 | 0 |
| 2024-07-19 | 17.5 | 0 | PUT | 0 | 0 | 169.12 | TRUE | 0 | 0 |
| 2024-07-19 | 20 | 0 | PUT | 0 | 0 | 175.98 | TRUE | 0 | 0 |
| 2024-10-18 | 2.5 | 7 | CALL | 0 | 1 | 238.84 | TRUE | 0 | 0 |
| 2024-10-18 | 5 | 3.2 | CALL | 0 | 3 | 77.88 | TRUE | 0 | 0 |
| 2024-10-18 | 7.5 | 1.55 | CALL | 50 | 149 | 69.31 | TRUE | -0.2 | -0.11 |
| 2024-10-18 | 10 | 0.8 | CALL | 8 | 203 | 70.53 | FALSE | -0.05 | -0.06 |
| 2024-10-18 | 12.5 | 0.45 | CALL | 0 | 70 | 63.6 | FALSE | 0 | 0 |
| 2024-10-18 | 15 | 0.3 | CALL | 0 | 40 | 83.15 | FALSE | 0 | 0 |
| 2024-10-18 | 17.5 | 0 | CALL | 0 | 0 | 86.95 | FALSE | 0 | 0 |
| 2024-10-18 | 2.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-10-18 | 5 | 0.2 | PUT | 0 | 13 | 73.1 | FALSE | 0 | 0 |
| 2024-10-18 | 7.5 | 1.35 | PUT | 25 | 18 | 71.57 | FALSE | 1.35 | 0 |
| 2024-10-18 | 10 | 3 | PUT | 4 | 15 | 69.18 | TRUE | 3 | 0 |
| 2024-10-18 | 12.5 | 4.2 | PUT | 0 | 3 | 64.3 | TRUE | 0 | 0 |
| 2024-10-18 | 15 | 6.78 | PUT | 0 | 6 | 80.08 | TRUE | 0 | 0 |
| 2024-10-18 | 17.5 | 9.2 | PUT | 0 | 21 | 140.79 | TRUE | 0 | 0 |
Latest VYGR Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:59 PM EST | 67 | $4.985 |
| Jun 13, 2022 7:59 PM EST | 3 | $4.985 |
| Jun 13, 2022 7:59 PM EST | 18 | $4.99 |
| Jun 13, 2022 7:59 PM EST | 17 | $4.99 |
| Jun 13, 2022 7:59 PM EST | 100 | $4.985 |
Voyager Therapeutics, Inc (VYGR) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1640266/000110465920071432/0001104659-20-071432-index.htm |
| 2019-11-19 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1640266/000000000019015636/0000000000-19-015636-index.htm |
| 2019-02-08 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1640266/000021545719006579/0000215457-19-006579-index.htm |
| 2018-08-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1640266/000031506618002168/0000315066-18-002168-index.htm |
| 2019-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1640266/000031506619001427/0000315066-19-001427-index.htm |
| 2020-02-06 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1640266/000083423720006893/0000834237-20-006893-index.htm |
| 2018-06-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000089924318017586/0000899243-18-017586-index.htm |
| 2018-06-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000089924318017587/0000899243-18-017587-index.htm |
| 2018-09-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000089924318024774/0000899243-18-024774-index.htm |
| 2018-09-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000089924318024777/0000899243-18-024777-index.htm |
| 2018-09-21 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1640266/000091957418006282/0000919574-18-006282-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1640266/000091957419001760/0000919574-19-001760-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1640266/000091957420001444/0000919574-20-001444-index.htm |
| 2020-03-05 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1640266/000091957420002138/0000919574-20-002138-index.htm |
| 2019-11-06 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1640266/000104746919006100/0001047469-19-006100-index.htm |
| 2019-12-03 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1640266/000104746919006602/0001047469-19-006602-index.htm |
| 2018-03-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465918019018/0001104659-18-019018-index.htm |
| 2018-03-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465918020100/0001104659-18-020100-index.htm |
| 2018-04-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465918023708/0001104659-18-023708-index.htm |
| 2018-05-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1640266/000110465918036438/0001104659-18-036438-index.htm |
| 2018-06-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1640266/000110465918038314/0001104659-18-038314-index.htm |
| 2018-06-15 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465918040463/0001104659-18-040463-index.htm |
| 2018-06-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1640266/000110465918040465/0001104659-18-040465-index.htm |
| 2018-06-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465918040887/0001104659-18-040887-index.htm |
| 2018-06-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465918040889/0001104659-18-040889-index.htm |
| 2018-06-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465918040890/0001104659-18-040890-index.htm |
| 2018-06-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465918040891/0001104659-18-040891-index.htm |
| 2018-06-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465918040892/0001104659-18-040892-index.htm |
| 2018-06-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465918040894/0001104659-18-040894-index.htm |
| 2018-06-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465918040895/0001104659-18-040895-index.htm |
| 2018-06-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1640266/000110465918042962/0001104659-18-042962-index.htm |
| 2018-07-18 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465918045812/0001104659-18-045812-index.htm |
| 2018-07-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465918045813/0001104659-18-045813-index.htm |
| 2018-08-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465918053030/0001104659-18-053030-index.htm |
| 2018-09-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465918056499/0001104659-18-056499-index.htm |
| 2018-09-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465918056500/0001104659-18-056500-index.htm |
| 2018-11-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465918067413/0001104659-18-067413-index.htm |
| 2019-01-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465919002346/0001104659-19-002346-index.htm |
| 2019-01-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465919002347/0001104659-19-002347-index.htm |
| 2019-01-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465919002348/0001104659-19-002348-index.htm |
| 2019-01-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465919002349/0001104659-19-002349-index.htm |
| 2019-01-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1640266/000110465919003840/0001104659-19-003840-index.htm |
| 2019-02-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1640266/000110465919009995/0001104659-19-009995-index.htm |
| 2019-02-26 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1640266/000110465919010753/0001104659-19-010753-index.htm |
| 2019-03-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1640266/000110465919014279/0001104659-19-014279-index.htm |
| 2019-04-03 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465919019771/0001104659-19-019771-index.htm |
| 2019-04-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465919019772/0001104659-19-019772-index.htm |
| 2019-05-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1640266/000110465919030857/0001104659-19-030857-index.htm |
| 2019-05-22 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465919031176/0001104659-19-031176-index.htm |
| 2019-05-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465919031178/0001104659-19-031178-index.htm |
| 2019-06-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1640266/000110465919035658/0001104659-19-035658-index.htm |
| 2019-06-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1640266/000110465919035796/0001104659-19-035796-index.htm |
| 2019-06-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465919035995/0001104659-19-035995-index.htm |
| 2019-06-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465919035996/0001104659-19-035996-index.htm |
| 2019-06-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465919035997/0001104659-19-035997-index.htm |
| 2019-06-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465919035998/0001104659-19-035998-index.htm |
| 2019-06-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465919036000/0001104659-19-036000-index.htm |
| 2019-06-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465919036003/0001104659-19-036003-index.htm |
| 2019-06-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465919036004/0001104659-19-036004-index.htm |
| 2019-06-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465919036005/0001104659-19-036005-index.htm |
| 2019-11-22 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1640266/000110465919066634/0001104659-19-066634-index.htm |
| 2019-11-27 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1640266/000110465919068177/0001104659-19-068177-index.htm |
| 2020-01-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465920008187/0001104659-20-008187-index.htm |
| 2020-01-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465920008188/0001104659-20-008188-index.htm |
| 2020-01-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465920008190/0001104659-20-008190-index.htm |
| 2020-02-11 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1640266/000110465920016411/0001104659-20-016411-index.htm |
| 2020-02-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465920019448/0001104659-20-019448-index.htm |
| 2020-02-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465920019453/0001104659-20-019453-index.htm |
| 2020-02-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465920019455/0001104659-20-019455-index.htm |
| 2020-02-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465920019457/0001104659-20-019457-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1640266/000110465920021672/0001104659-20-021672-index.htm |
| 2020-02-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1640266/000110465920021963/0001104659-20-021963-index.htm |
| 2020-03-03 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1640266/000110465920028678/0001104659-20-028678-index.htm |
| 2020-03-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1640266/000110465920035610/0001104659-20-035610-index.htm |
| 2020-04-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465920044247/0001104659-20-044247-index.htm |
| 2020-05-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465920065492/0001104659-20-065492-index.htm |
| 2020-06-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465920070318/0001104659-20-070318-index.htm |
| 2020-06-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465920070323/0001104659-20-070323-index.htm |
| 2020-06-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465920070326/0001104659-20-070326-index.htm |
| 2020-06-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465920070327/0001104659-20-070327-index.htm |
| 2020-06-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465920070328/0001104659-20-070328-index.htm |
| 2020-06-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465920070329/0001104659-20-070329-index.htm |
| 2020-06-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465920070330/0001104659-20-070330-index.htm |
| 2020-06-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1640266/000110465920071432/0001104659-20-071432-index.htm |
| 2020-08-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1640266/000110465920089624/0001104659-20-089624-index.htm |
| 2020-09-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1640266/000110465920105222/0001104659-20-105222-index.htm |
| 2020-09-16 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465920105664/0001104659-20-105664-index.htm |
| 2020-09-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000110465920105669/0001104659-20-105669-index.htm |
| 2019-04-01 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1640266/000114420419017415/0001144204-19-017415-index.htm |
| 2019-02-11 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1640266/000119312519033129/0001193125-19-033129-index.htm |
| 2019-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1640266/000119312519037847/0001193125-19-037847-index.htm |
| 2019-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1640266/000119312519037913/0001193125-19-037913-index.htm |
| 2019-02-15 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1640266/000119312519042298/0001193125-19-042298-index.htm |
| 2020-02-11 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1640266/000119312520030574/0001193125-20-030574-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1640266/000119312520037830/0001193125-20-037830-index.htm |
| 2019-03-14 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000120919119019450/0001209191-19-019450-index.htm |
| 2019-03-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1640266/000120919119019459/0001209191-19-019459-index.htm |
| 2018-04-27 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1640266/000155837018003377/0001558370-18-003377-index.htm |
| 2018-05-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1640266/000155837018004570/0001558370-18-004570-index.htm |
| 2018-05-10 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1640266/000155837018004575/0001558370-18-004575-index.htm |
| 2018-08-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1640266/000155837018006605/0001558370-18-006605-index.htm |
| 2018-08-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1640266/000155837018006628/0001558370-18-006628-index.htm |
| 2018-11-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1640266/000155837018008805/0001558370-18-008805-index.htm |
| 2018-11-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1640266/000155837018008821/0001558370-18-008821-index.htm |
| 2019-02-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1640266/000155837019001085/0001558370-19-001085-index.htm |
| 2019-02-26 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1640266/000155837019001105/0001558370-19-001105-index.htm |
| 2019-04-23 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1640266/000155837019003181/0001558370-19-003181-index.htm |
| 2019-05-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1640266/000155837019004159/0001558370-19-004159-index.htm |
| 2019-05-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1640266/000155837019004165/0001558370-19-004165-index.htm |
| 2019-08-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1640266/000155837019007805/0001558370-19-007805-index.htm |
| 2019-08-09 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1640266/000155837019007823/0001558370-19-007823-index.htm |
| 2019-11-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1640266/000155837019010064/0001558370-19-010064-index.htm |
| 2019-11-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1640266/000155837019010066/0001558370-19-010066-index.htm |
| 2020-03-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1640266/000155837020001965/0001558370-20-001965-index.htm |
| 2020-03-03 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1640266/000155837020001974/0001558370-20-001974-index.htm |
| 2020-04-22 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1640266/000155837020004158/0001558370-20-004158-index.htm |
| 2020-05-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1640266/000155837020005285/0001558370-20-005285-index.htm |
| 2020-05-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1640266/000155837020005300/0001558370-20-005300-index.htm |
| 2020-08-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1640266/000155837020010039/0001558370-20-010039-index.htm |
| 2020-08-10 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1640266/000155837020010047/0001558370-20-010047-index.htm |
| 2019-03-14 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1640266/000156459019007831/0001564590-19-007831-index.htm |
| 2019-12-02 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1640266/999999999519002724/9999999995-19-002724-index.htm |
| 2018-04-05 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1640266/999999999718004233/9999999997-18-004233-index.htm |
| 2019-03-19 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1640266/999999999719001305/9999999997-19-001305-index.htm |
Voyager Therapeutics, Inc (VYGR) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Voyager Therapeutics, Inc (VYGR). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 1407%Institutional Ownership: 7493%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2018-04-10 | Bernard Ravina | Chief Medical Officer | Sell | 2,451.00 | 18.38 | 45,049.38 | 0.00 | https://www.sec.gov/Archives/edgar/data/1640266/000110465918023708/0001104659-18-023708-index.htm |
| 2018-03-16 | Jane Henderson | CFO & SVP, Corp. Dev. | Sell | 15,416.00 | 22.15 | 341,464.40 | 0.00 | https://www.sec.gov/Archives/edgar/data/1640266/000110465918019018/0001104659-18-019018-index.htm |
| 2018-03-19 | Jane Henderson | CFO & SVP, Corp. Dev. | Sell | 1,900.00 | 21.76 | 41,344.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1640266/000110465918019018/0001104659-18-019018-index.htm |
| 2018-03-22 | Jane Henderson | Sr. V.P. & CFO, Corp. Dev. | Sell | 19,900.00 | 21.07 | 419,293.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1640266/000110465918020100/0001104659-18-020100-index.htm |
| 2018-03-23 | Jane Henderson | Sr. V.P. & CFO, Corp. Dev. | Sell | 11,200.00 | 20.52 | 229,824.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1640266/000110465918020100/0001104659-18-020100-index.htm |
| 2018-03-23 | Jane Henderson | Sr. V.P. & CFO, Corp. Dev. | Buy | 11,200.00 | 11.97 | 134,064.00 | 11,200.00 | https://www.sec.gov/Archives/edgar/data/1640266/000110465918020100/0001104659-18-020100-index.htm |
| 2018-03-16 | Jane Henderson | CFO & SVP, Corp. Dev. | Buy | 15,416.00 | 11.97 | 184,529.52 | 15,416.00 | https://www.sec.gov/Archives/edgar/data/1640266/000110465918019018/0001104659-18-019018-index.htm |
| 2019-01-11 | Dinah Ph.D. Sah | Chief Scientific Officer | Buy | 25,000.00 | 163,688.00 | https://www.sec.gov/Archives/edgar/data/1640266/000110465919002348/0001104659-19-002348-index.htm | ||
| 2020-02-10 | Andre Turenne | President & CEO | Buy | 81,250.00 | 166,795.00 | https://www.sec.gov/Archives/edgar/data/1640266/000110465920019448/0001104659-20-019448-index.htm | ||
| 2018-03-19 | Jane Henderson | CFO & SVP, Corp. Dev. | Buy | 1,900.00 | 11.97 | 22,743.00 | 1,900.00 | https://www.sec.gov/Archives/edgar/data/1640266/000110465918019018/0001104659-18-019018-index.htm |
| 2018-03-22 | Jane Henderson | Sr. V.P. & CFO, Corp. Dev. | Buy | 19,900.00 | 11.97 | 238,203.00 | 19,900.00 | https://www.sec.gov/Archives/edgar/data/1640266/000110465918020100/0001104659-18-020100-index.htm |
| 2020-01-21 | Allison Dorval | Chief Financial Officer | Sell | 3,128.00 | 13.36 | 41,790.08 | 24,522.00 | https://www.sec.gov/Archives/edgar/data/1640266/000110465920008190/0001104659-20-008190-index.htm |
| 2019-01-11 | Allison Dorval | Chief Financial Officer | Buy | 25,000.00 | 26,106.00 | https://www.sec.gov/Archives/edgar/data/1640266/000110465919002346/0001104659-19-002346-index.htm | ||
| 2020-01-21 | Matthew P. Ottmer | Chief Operating Officer | Sell | 3,724.00 | 13.36 | 49,752.64 | 26,276.00 | https://www.sec.gov/Archives/edgar/data/1640266/000110465920008188/0001104659-20-008188-index.htm |
| 2019-04-01 | Robert W. Hesslein | Senior VP & General Counsel | Buy | 28,125.00 | 28,125.00 | https://www.sec.gov/Archives/edgar/data/1640266/000110465919019772/0001104659-19-019772-index.htm | ||
| 2019-01-11 | Matthew P. Ottmer | Chief Operating Officer | Buy | 30,000.00 | 30,000.00 | https://www.sec.gov/Archives/edgar/data/1640266/000110465919002347/0001104659-19-002347-index.htm | ||
| 2019-05-20 | Omar Khwaja | Officer | Buy | 30,000.00 | 30,000.00 | https://www.sec.gov/Archives/edgar/data/1640266/000110465919031178/0001104659-19-031178-index.htm | ||
| 2019-03-12 | NEUROCRINE BIOSCIENCES INC | 10% Share Holder | Buy | 4,179,728.00 | 11.96 | 49,999,996.20 | 4,179,728.00 | https://www.sec.gov/Archives/edgar/data/1640266/000120919119019459/0001209191-19-019459-index.htm |
| 2018-09-12 | GLENN PIERCE | Director | Buy | 5,000.00 | 18.44 | 92,200.00 | 5,000.00 | https://www.sec.gov/Archives/edgar/data/1640266/000110465918056499/0001104659-18-056499-index.htm |
| 2020-02-10 | Allison Dorval | Chief Financial Officer | Buy | 27,500.00 | 52,022.00 | https://www.sec.gov/Archives/edgar/data/1640266/000110465920019457/0001104659-20-019457-index.htm | ||
| 2020-04-03 | Robert W. Hesslein | Senior VP & General Counsel | Sell | 3,091.00 | 8.51 | 26,304.41 | 52,534.00 | https://www.sec.gov/Archives/edgar/data/1640266/000110465920044247/0001104659-20-044247-index.htm |
| 2020-02-10 | Robert W. Hesslein | Senior VP & General Counsel | Buy | 27,500.00 | 55,625.00 | https://www.sec.gov/Archives/edgar/data/1640266/000110465920019455/0001104659-20-019455-index.htm | ||
| 2020-05-21 | Omar Khwaja | Officer | Sell | 3,500.00 | 12.96 | 45,360.00 | 56,500.00 | https://www.sec.gov/Archives/edgar/data/1640266/000110465920065492/0001104659-20-065492-index.htm |
| 2020-02-10 | Omar Khwaja | Officer | Buy | 30,000.00 | 60,000.00 | https://www.sec.gov/Archives/edgar/data/1640266/000110465920019453/0001104659-20-019453-index.htm | ||
| 2018-08-17 | JAMES A GERAGHTY | Director | Buy | 3,000.00 | 18.31 | 54,930.00 | 73,588.00 | https://www.sec.gov/Archives/edgar/data/1640266/000110465918053030/0001104659-18-053030-index.htm |
| 2018-09-10 | JAMES A GERAGHTY | Director | Buy | 3,000.00 | 19.39 | 58,170.00 | 76,588.00 | https://www.sec.gov/Archives/edgar/data/1640266/000110465918056500/0001104659-18-056500-index.htm |
| 2020-01-21 | Andre Turenne | President & CEO | Sell | 10,705.00 | 13.36 | 143,018.80 | 85,545.00 | https://www.sec.gov/Archives/edgar/data/1640266/000110465920008187/0001104659-20-008187-index.htm |
| 2019-01-11 | Andre Turenne | President & CEO | Buy | 96,250.00 | 96,250.00 | https://www.sec.gov/Archives/edgar/data/1640266/000110465919002349/0001104659-19-002349-index.htm |